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Abstract. This article provides an overview of the ethical issues raised by the use of non-human primates
(NHPs) in research involving scientiﬁc procedures which may cause pain, suﬀering, distress or lasting harm. It
is not an exhaustive review of the literature and views on this subject, and it does not present any conclusions
about the moral acceptability or otherwise of NHP research. Rather the aim has been to identify the ethical
issues involved and to provide guidance on how these might be addressed, in particular by carefully examining
the scientiﬁc rationale for NHP use, implementing fully the 3Rs principle of Russell and Burch (1959) and
applying a robust “harm-beneﬁt assessment” to research proposals involving NHPs.
1 Introduction
1.1 NHP use in scientiﬁc procedures
NHPs are among the most extensively studied of all ani-
mals in the ﬁelds of behaviour, psychology, ecology, con-
servation and anthropology (see the PrimateLit bibliographic
database: http://primatelit.library.wisc.edu/). They are also
used in biomedical and biological research involving regu-
lated scientiﬁc procedures, mainly in the ﬁelds of microbi-
ology, immunology, neuroscience, biochemistry, pharmacol-
ogy and toxicology, because their physiological and psycho-
logical similarities to humans make them high ﬁdelity mod-
els1 (Carlsson et al., 2004; Hau et al., 2000; Weatherall et
al., 2006). The majority are Old World monkeys (macaques,
vervet monkeys and baboons), both purpose-bred and wild-
caught; New World monkeys, Prosimians and Great Apes
(chimpanzees, Pan troglodytes) are also used2 (Carlsson et
al., 2004; Conlee et al., 2004; European Commission, 2007;
Hagelin, 2004; Rennie and Buchanan-Smith, 2005). An esti-
mated100000–200000NHPsareusedannuallyworld-wide,
mostly in the United States of America (USA), the European
Union (EU) and Japan (Carlsson et al., 2004). Currently
Correspondence to: M. J. Prescott
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1That is not to say that NHP models do not have limitations
(e.g. Lewis and Johnson, 1995).
2The last recorded Great Ape use in the EU was in 1999
(6 chimpanzees).
their use within the pharmaceutical industry is rising in line
with the increasing number of biopharmaceuticals entering
the drugs pipeline (Chapman et al., 2010; Hobson, 2000).
1.2 Views on NHP use
The use of NHPs in scientiﬁc procedures is one of the most
contentious issues in science. At the time of writing, this
issue is high on the political agenda in the EU, following
a proposal from the European Commission (2008) to revise
“Directive 86/609/EEC on the Protection of Animals Used
for Experimental and Other Scientiﬁc Purposes” (European
Community, 1986) and an opinion from its Scientiﬁc Com-
mittee on Health and Environmental Risks (2009) on “The
need for non-human primates in biomedical research, pro-
duction and testing of products and devices”. The revision
provides the opportunity for the EU Parliament and Council
of Ministers to introduce new restrictions on NHP use. Al-
though NHPs account for a very small proportion of the total
number of vertebrate animals used in scientiﬁc procedures
(0.09% of those used in the EU in 2005: European Com-
mission, 2007), opinion polls repeatedly show a high level
of concern about their use amongst the general public (Euro-
pean Commission, 2006; New Scientist/MORI, 1999; Pifer
et al., 1994). For example, more than 80% of respondents to
the Commission’s 2006 public consultation on animal exper-
iments considered the use of NHPs to be not acceptable.
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Glossary
Deontological ethics: An approach to ethics that judges the
morality of an action based on the action’s adherence to a rule
or rules. Deontologists look at rules and duties.
Transgenesis: The process of introducing foreign DNA into a
genome.
Pharmacokinetics: A branch of pharmacology dedicated to
the determination of the fate of substances administered exter-
nally to a living organism.
Phylogenetic: Relating to or based on evolutionary develop-
ment or history.
Neurophysiological: Relating to the function of the nervous
system.
Neurovirulence: The tendency or capacity of a micro-
organism to cause disease of the nervous system.
Theory of mind: The ability to attribute mental states (e.g. be-
liefs, desires and intentions) to oneself and others and to un-
derstand that others have beliefs, desires and intentions that are
diﬀerent from one’s own.
Utilitarianism: The idea that the moral worth of an action is
determined solely by its utility in providing happiness or plea-
sure as summed among all sentient beings. It is thus a form of
consequentialism meaning that the moral worth of an action is
determined by its outcome.
The consensus within the scientiﬁc community is that
the close phylogenetic relationship of NHPs with humans
makes them the best available animal models for particular
research questions, and that, in the absence of suitable alter-
natives, their appropriate use remains essential in certain ar-
eas of biomedical and biological research and for the safety
assessment of pharmaceuticals (Hau et al., 2000; Hobson,
2000; National Research Council, 2003; Scientiﬁc Commit-
tee on Health and Environmental Risks, 2009; Weatherall
et al., 2006). Many antivivisection and animal welfare or-
ganisations, however, argue that it is this same relationship
that causes them to object to NHP research, since it implies
that NHPs can suﬀer in similar ways to humans. Further-
more, NHPs cannot consent to their own participation in re-
search and, generally, will not beneﬁt from such participa-
tion. For these reasons, the animal protection community
believes that NHP experiments are unethical and should be
banned or rapidly phased-out (Balls, 2000; Eurogroup for
Animal Welfare, 2005; Humane Society of the United States,
2009; Thew and Seymour, 2009). Both communities have
at times used the scientiﬁc literature selectively to support
sweeping statements about the scientiﬁc validity, utility and
moral acceptability of NHP use as a whole; this is irresponsi-
bleandmisleading, andperpetuatesentrenchedandpolarised
viewpoints.
2 Ethical frameworks and legal controls applied
to NHP use
The fundamental ethical dilemma raised by the use of NHP
in experiments is the same as for the use of other animals: are
we, human beings, morally justiﬁed in causing animals pain,
suﬀering, distress and/or lasting harm in research aimed at
alleviating or preventing human suﬀering, or furthering sci-
entiﬁc knowledge. There is a wide spectrum of views on this
issue in society, from those who consider all animal experi-
ments to be immoral to those who believe few animal exper-
iments to be unjustiﬁed if they beneﬁt humans in some way
(Nuﬃeld Council on Bioethics, 2005). Moreover, many peo-
ple hold varying opinions depending on the precise circum-
stances in question (e.g. the purpose of the research and the
anticipated beneﬁt, the species to be used, the level of harm
caused to the animals involved). Therefore, most committees
responsible for scrutinising the ethics of animal research pro-
posals, whether at a institutional, local, regional or national
level, aim to reach a collective decision, involving a diver-
sity of perspectives and expertise (e.g. in the scientiﬁc area
in question, animal welfare and ethics) (Animal Procedures
Committee, 2009; de Greeve and de Leeuw, 1999; Home Of-
ﬁce, 1998; Kolar, 2004).
2.1 Utilitarianism and the harm-beneﬁt assessment
The approach to the ethical dilemma most often adopted is
a pragmatic, utilitarian one. Utilitarianism requires us to
strike the most favourable balance of beneﬁts and costs for
all the sentient individuals aﬀected by what is proposed to be
done. The underlying notion is that we can work out what
is the ethical course of action by trading oﬀ one against the
other (although this precept has been attacked by some moral
philosophers). In the case of NHP research, the human inter-
est in obtaining some beneﬁt for mankind must be balanced
against the interests of the NHPs in avoiding harm (Quigley,
2007).
This approach, referred to as a “cost-beneﬁt assessment”
or “harm-beneﬁt assessment”, forms the cornerstone of the
United Kingdom (UK) Animals (Scientiﬁc Procedures) Act
1986 (ASPA) (UK Government, 1986). The Act is unique in
explicitly requiring a harm-beneﬁt assessment of every ap-
plication to the Home Oﬃce for a project licence to conduct
animal research. The European Commission (2008) intends
that a harm-beneﬁt assessment be part of the ethical evalu-
ation of research projects by national regulatory authorities
under the revised Directive 86/609/EEC, and there have been
calls for such an assessment to be applied to NHP use in the
USA (Conlee et al., 2004)3.
3The Institutional Animal Care and Use Committees required in
the USA under the amended 1966 Animal Welfare Act and
1985 Health Research Extension Act are concerned with
animal care and use; not ethics.
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2.2 The 3Rs
The moral acceptability of animal research is less question-
able where animal use and suﬀering are minimised, in line
with the 3Rs principle of Russell and Burch (1959):
– Replacement of animals with non-animal methods;
– Reduction of the number of animals used to obtain in-
formation of a given amount and precision;
– Reﬁnement of scientiﬁc procedures and husbandry to
minimise suﬀering and improve animal welfare.
In addition to its value as an ethical framework for hu-
mane experiments, the 3Rs principle has considerable sci-
entiﬁc merit and receives tacit support from the general pub-
lic in opinion polls on animal experimentation (Ipsos MORI,
2009). Hence, it features in most codes of conduct on animal
research and, in developed countries at least, scientists are
required by law to apply something like it (European Com-
munity, 1986; Shoji, 2008; UK Government, 1986; United
States Department of Agriculture, 1990). For example, Ar-
ticle 7 of Directive 86/609/EEC states “an experiment shall
not be performed if another scientiﬁcally satisfactory method
of obtaining the result sought, not entailing the use of an ani-
mal, is reasonably and practicably available” and “When an
experiment has to be performed, the choice of species shall
be carefully considered and, where necessary, explained to
the authority. In a choice between experiments, those which
use the minimum number of animals, involve animals with
the lowest degree of neurophysiological sensitivity, cause
the least pain, suﬀering, distress or lasting harm and which
are most likely to provide satisfactory results shall be se-
lected”.
2.3 Responsibilities
There is broad support within the scientiﬁc and animal wel-
fare communities for application of the 3Rs and a harm-
beneﬁt assessment to NHP research such that NHPs are only
used in experiments where absolutely necessary (i.e. where
no alternative methods are available), where morally justi-
ﬁed, and where the numbers used and animal suﬀering are
kept to the minimum (Boyd Group, 2002; Joint Working
Group on Reﬁnement, 2009; Scientiﬁc Committee on Health
and Environmental Risks, 2009; Weatherall et al., 2006).
Such judgements can only be made case-by-case for individ-
ual scientiﬁc objectives and projects (see Sect. 4) and usually
involve the researcher, relevant ethics committee and/or na-
tional regulatory authority. Increasingly, public bodies fund-
ing NHP research, such as the European Commission, Med-
ical Research Council, Biotechnology and Biological Sci-
ences Research Council and Wellcome Trust, are also taking
an active role in examining the necessity, justiﬁcation and
standards for such research (e.g. during the peer review of
research grant applications) (Kolar, 2004; National Centre
for the Replacement, Reﬁnement and Reduction of Animals
in Research, 2006a).
2.4 Special legal provisions on NHPs
In recognition of the high levels of public concern about
NHP research, regulatory authorities in some countries have
adopted strict measures on NHP use, eﬀectively establishing
ethical limits, giving rise to regulation which is a hybrid of
deontological and utilitarian ethics. For example, under the
UK ASPA, NHPs, together with cats, dogs and equines, can
only be used where animals of no other species are suitable
for achieving the scientiﬁc objective. Since 1995, there has
also been an administrative ban on the use of Great Apes in
scientiﬁc procedures (the UK Government will not issue li-
censes for their use), a ban on the use of wild-caught NHPs
exceptwhereexceptionallyandspeciﬁcallyjustiﬁed, andfur-
ther controls on the acquisition and use of NHPs (Home Of-
ﬁce, 2000). Directive 86/609/EEC (European Community
1986) does not aﬀord such special protection to NHPs (al-
though “degree of neurophysiological sensitivity” is a con-
sideration) but similar prohibitions are proposed for the re-
vised Directive (see European Commission, 2008). There
are special provisions under the USA Animal Welfare Act
(United States Department of Agriculture, 1990) regarding
environmental enhancement to promote the psychological
well-being of captive NHPs, and governments in many na-
tions have established accommodation and care requirements
for these animals (Council of Europe, 2006; Home Oﬃce,
1989; National Research Council, 1996) (see Sect. 3.3).
3 Are NHPs worthy of special concern?
3.1 What are the ethical issues?
Many of the ethical issues associated with NHP use in sci-
entiﬁc procedures are the same as those raised by the use of
other vertebrate animals (Olsson et al., 2003):
– Exposure to painful or distressing scientiﬁc procedures
and their eﬀects, such as surgical interventions, infec-
tious disease, or restraint – however, the suﬀering of
NHPs may be diﬀerent in kind from that of other ani-
mals (see Sect. 3.2);
– Housing in captive environments which limit freedom
and may not meet species-typical needs, giving rise to
physical or mental suﬀering (see Sect. 3.3) – these is-
sues apply to breeding animals also;
– Death – very often this is required as an integral part of
the experiment, because of the need to analyse tissues
post mortem (see Sect. 3.4).
The purpose for which the animals are used can also raise
ethical concerns (see Sect. 4.3), as can the application of new
technologies (e.g. transgenesis: Olsson and Sandøe, 2009;
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Schatten and Mitalipov, 2009; Coors et al., 2010; engraft-
ment of human neural stem cells: Greene et al., 2005).
In addition, practical issues related to the maintenance and
use of NHPs raise ethical concerns that do not apply to most
other animals used in research, for example:
– NHPs typically have long life spans and can spend years
in captivity undergoing lengthy experiments (e.g. in be-
havioural neuroscience), continued use (e.g. in phar-
macokinetics) or re-use in several independent studies
during the course of their lives (see Sect. 4.2.2) (Carls-
son et al., 2004; Rennie and Buchanan-Smith, 2005;
Scientiﬁc Committee on Animal Health and Welfare,
2002).
– The inability of captive breeding colonies in the EU
and USA to satisfy the research demand for macaques
and other NHP species necessitates their importation
from source countries in Asia, Africa and South Amer-
ica (Cohen, 2000; Hau and Schapiro, 2006; National
Research Council, 2003; Prescott, 2001). The long,
multi-staged journeys involved and the housing condi-
tions, weaning and quarantine practices prior to impor-
tation can have ethical and animal welfare implications
(Animal Procedures Committee, 2006; Fernstrom et al.,
2008; Honess et al., 2004; Prescott and Jennings, 2004).
– Practically all of the NHPs used in research in the EU
are purpose-bred, but most of the Old World monkeys
used are the oﬀspring of wild-caught parents (F1 gen-
eration) (Scientiﬁc Committee on Health and Environ-
mental Risks, 2009). The capture and use of wild-
caught NHPs for breeding for research has been crit-
icised (Scientiﬁc Committee on Animal Health and
Welfare, 2002), because of the stress, morbidity and
mortality involved (International Primatological Soci-
ety, 2007; Suleman et al., 1999, 2000). However, it has
been argued that establishing and replenishing breed-
ing colonies with wild-caught NHPs can be ethically
justiﬁed where the animals are agricultural pests and
would otherwise be killed (Stanley, 2003). To decrease
reliance on wild-caught NHPs for breeding, the Euro-
pean Commission (2008) has proposed that after spe-
ciﬁctimelinesonlysecondgeneration(F2)animalsborn
in captivity should be used in research.
3.2 Suffering and the moral status of NHPs
Many people, including from within the scientiﬁc commu-
nity, consider that the use of NHPs in research is a matter
of particular ethical concern because certain features NHPs
share with humans, such as their highly developed nervous
systems, cognitive complexity and intense sociality, have im-
plications for the level or nature of suﬀering they might expe-
rience during experiments and are therefore morally relevant
(Boyd Group, 2002; Nuﬃeld Council on Bioethics, 2005;
Weatherall et al., 2006). It is extremely diﬃcult to deter-
mine exactly the subjective experiences of non-human ani-
mals in relation to pain and suﬀering. However, the evolu-
tionary continuum that is obvious from physiological, neuro-
logical and behavioural similarities between humans, NHPs
and other animals allows us to make meaningful approxima-
tions.
A great deal is known about the nervous systems of
NHP species (particularly macaques) from their use in in-
vasive neuroscience research as a model of the human brain
(Peretta, 2009). It seems plausible that NHPs have the po-
tential to experience pain in a similar way to humans, given
their neurophysiological complexity. However, the issue is
not just response to pain, but the ability to anticipate and re-
ﬂect upon pain, as well as for painful memories to endure
after a painful episode, which could enhance any suﬀering
(Bateson, 1991; Bermond, 2001; Lea, 2001). The evidence
for reﬂective self-awareness of this kind is strongest for the
Great Apes (Call and Tomasello, 2008; Parker et al., 1994),
which raises serious questions about the morality of using
them in harmful scientiﬁc procedures (Balls, 2007; Byrne,
1999; Knight, 2008). Such considerations have probably
played an instrumental role in the decisions of some coun-
tries, including the UK, the Netherlands, Austria, Belgium,
Sweden, New Zealand, Australia and Japan, to ban the use
of Great Apes in biomedical research or place a strong mora-
torium on their use. To what extent biomedical researchers
from these countries make use of Great Apes in countries
where they still can be used, such as the USA, is not known.
Many characteristics of the Great Apes are considered in-
dicators of “humanhood” or “personhood”, such as their self-
recognition(andbyimplicationself-awareness), rudimentary
“theory of mind”, linguistic abilities, distinct personalities,
deep emotional attachments, and ability to pass on learned
behaviours and customs through social mechanisms (G´ omez,
1998; Scientiﬁc Committee on Animal Health and Welfare,
2002). This had led to calls to extend to Great Apes the
same moral status aﬀorded to humans and to confer on them
the same legal rights as humans to life, individual liberty
and freedom from torture (Anonymous, 2008; Bekoﬀ, 1997;
Cavalieri and Singer, 1993; Wise, 2000; The Great Ape
Project: http://en.wikipedia.org/wiki/Great Ape Project).
The Old and New World monkeys more commonly used in
research do not appear to share the most sophisticated men-
tal abilities of Great Apes. Nonetheless, in the view of the
Boyd Group, a forum for open exchange of views on issues
of concern related to the use of animals in science “there is
strong, though not incontestable, evidence that the general
richness of monkeys’ social lives and mental abilities means
that compromising their way of life by using them in research
and testing has the potential to cause them greater social and
mental suﬀering than other laboratory species” (see Boyd
Group, 2002 for a discussion of the evidence).
The intense sociality of NHPs is striking and sug-
gests that they may suﬀer comparatively more than other
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commonly-used animals from conﬁnement and relative so-
cialisolation. Certainly, theworkofHarryHarlowandothers
(e.g. Harlow, 1958; Law, 2009; Rosenblum and Paully, 1987)
on monkey cognition and social development has demon-
stratedthattheseanimalshaverichsubjectivelivesﬁlledwith
intention and emotion, and that disrupting their social bonds
can cause depression-like states, with obvious ethical impli-
cations (Blum, 2002; Gluck, 1997; Novak and Suomi, 1991).
The relative moral status of monkeys compared with other
laboratory animals, particularly social mammals such as cats,
dogs, equines and pigs, is more contentious (e.g. Webster et
al., 2010). As pointed out by the Boyd Group (2002), it is
diﬃcult generally to ﬁnd ways of comparing the potential for
suﬀering of any given species with another species. More-
over, it is diﬃcult for us, as humans, to judge capacities for
suﬀering in, or to empathise with, species which are evo-
lutionarily more distant from us, and it might be argued that
according any species of monkey special moral status reﬂects
human prejudice in favour of species more like ourselves.
3.3 Housing in captivity
NHPs are essentially non-domesticated, wild animals mostly
adapted to complex tropical habitats. Conﬁning wild ani-
mals in captivity raises ethical concerns because it imposes
upon them an environment vastly diﬀerent from that in which
they have evolved; if they are not able to adapt to the captive
conditions, this can have a serious detrimental eﬀect on their
welfare (Carlstead, 1996). There is also a view that wild
animals have a right to liberty (Rachels, 1976). Although
functional simulations of many aspects of the natural envi-
ronments of NHPs can be replicated in captivity (Hau and
Schapiro, 2004) many scientists believe there are inherent
diﬃculties in meeting the complex social, behavioural and
psychological needs of NHPs in the laboratory environment
and that the minimum standards of accommodation and care
established by governments in many nations may not be suf-
ﬁcient to provide for their physical health and psychological
well-being(BoydGroup, 2002; Buchanan-Smithetal., 2004;
Faucheux et al., 1978; National Research Council, 1998; No-
vak and Suomi, 1988; Prescott and Buchanan-Smith, 2004;
Reinhardt, 2004; Savage-Rumbaugh et al., 2007; Scientiﬁc
Committee on Animal Health and Welfare, 2002; Wolfen-
sohn and Honess, 2005). Accordingly, major investments
to improve housing conditions for NHPs have been made in
recent years, with increased attention given to environmen-
tal enrichment and social housing, which has undoubtedly
improved animal welfare (e.g. Rudling, 2003; Kelly, 2008;
Waitt et al., 2008; Wolfensohn, 2008). However, there re-
mains considerable variation in standards between establish-
ments which has led research funding bodies to develop their
own higher standards for NHP research and to make adher-
ence to them a condition of funding, wherever the research is
conducted (Laboratory Animal Science Association/Medical
Research Council, 2004; National Centre for the Replace-
ment, Reﬁnement and Reduction of Animals in Research,
2006b).
3.4 Fate of the animals
The majority of NHPs used in experiments are euthanized,
either because their tissues are required as part of the exper-
iment or on compassionate grounds to alleviate unnecessary
suﬀering. Whether it is morally wrong to prematurely end an
animal’s life is a subject of philosophical debate and beyond
the scope of this chapter (see Regan, 1975). Apart from the
philosophical question of whether an animal is harmed by
being killed, in the case of highly sociable animals such as
NHPs, theimplicationsforothermembersofthesocialgroup
of losing a group member also may raise ethical concerns.
In situations where death is not required, for example, in
the case of surplus ex-research or ex-breeding NHPs, it is of-
ten possible to “retire” the animals and allow them to live out
their natural life spans (Brent, 2004; Kerwin, 2006; Prescott,
2006; Seelig and Truitt, 1999). Some establishments choose
this option on ethical grounds, where it is in the best inter-
ests of the animals concerned. NHPs are intelligent animals
with which it is possible to develop strong emotional bonds
(Bayne, 2002; Herzog, 2002); this can make euthanasia of
NHPs diﬃcult for staﬀ to accept (Abbot, 2008).
In the case of chimpanzees no longer needed for biomed-
ical research in the USA, retirement is a legal requirement
under the 2000 Chimpanzee Health Improvement, Mainte-
nance, and Protection Act. This Act established a system of
sanctuaries to provide lifetime care for surplus chimpanzees,
none of which may be subjected to euthanasia (except where
it is in the best interests of the chimpanzee involved).
4 Conducting ethical evaluations of NHP use
Given the high level of concern about NHP use, it is impor-
tant that ethical evaluations of primate experiments are ro-
bust and thorough. This requires case-by-case scrutiny of
the necessity and justiﬁcation for the use of NHPs, taking
into account the importance of the science, the likelihood
of success, the availability of alternatives, the real “added
value” of NHPs over and above other species and methods,
the number of animals to be used, and the total harms caused
to the animals throughout their lifetimes. Only by consid-
ering these issues together can truly informed decisions be
made about whether or not certain uses of NHPs are nec-
essary, justiﬁed and ethical. Some considerations are given
below, drawn from the author’s experience. The focus is on
NHP use in scientiﬁc procedures, but it is worth noting that
even observational studies in the ﬁeld can raise ethical issues,
particularly if provisioning, capture or marking are involved
(Fedigan, 2010; Gillespie et al., 2009; Jolly et al., 2003).
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4.1 Is the NHP use scientiﬁcally necessary?
In order to establish whether NHP use is scientiﬁcally neces-
sary, the researcher should set out in detail the reasons why
he/she believes that the particular scientiﬁc objective can-
not be achieved by means other than the use of NHPs, or
why NHPs oﬀer very signiﬁcant scientiﬁc advantages over
all other possible alternative approaches (e.g. signiﬁcantly
improved predictive value). The importance of achieving the
objective (e.g. in terms of the clinical need or commercial
interests) is not relevant in this context. The rationale for
NHP use should be critically examined by independent ex-
perts with a wide knowledge of the research ﬁeld in question,
including all available alternative approaches – not just those
based on NHPs; this may require a wider than normal pool
of scientiﬁc referees.
In most ﬁelds of research where NHPs are used, the sci-
entiﬁc justiﬁcation given for their use concerns their close
similarity to humans, which it is argued makes them the best
available model for deﬁned scientiﬁc questions. However,
generic appeals to this similarity should not be considered
suﬃcient justiﬁcation for NHP use. Instead, the rationale
should be speciﬁc and founded on robust scientiﬁc consid-
erations, such as the presence only in the NHP species of
the anatomical structures, pathways, cognitive abilities or be-
haviours of interest. References and information should be
provided which support the rationale and which demonstrate
an active search for alternatives.
Various regulatory guidelines on toxicity and safety as-
sessments of pharmaceuticals recommend that NHPs should
only be used when it is scientiﬁcally demonstrated that none
of the alternative rodent and/or non-rodent species com-
monly used in safety testing are appropriate for the purpose
of the study (International Conference on Harmonisation,
2009; Smith and Trennery, 2002). Therefore, proposals to
use NHPs for safety testing should receive as much scrutiny
as those proposing their use in biomedical and biological re-
search. NHPs should not be used as a default species, on the
assumption that they will be the only species representative
of humans (or the species most representative of humans) or
because they have been used previously.
One of the main factors driving a rise in NHP use world-
wide is the increasing development of monoclonal antibod-
ies (mAbs) as therapies for diseases such as cancer and
other immune-related conditions. mAbs are highly target-
and species-speciﬁc, so NHPs, typically cynomolgus mon-
keys (Macaca fascicularis), are often the only relevant ani-
mal model for preclinical safety studies. However, there are
safety-relevantdiﬀerencesbetweenNHPandhumanimmune
systems, even between chimpanzees and humans, which
means that NHPs are not always relevant for predicting hu-
man safety (Muller and Brennan, 2009); even where they
posses the intended drug target, the pharmacological activ-
ity may not be the same as in man (Chapman et al., 2009,
2010). Where NHP use is necessary, careful thought should
be given to species selection, taking into account scientiﬁc,
animal welfare and practical considerations (Boyd Group,
2002; Smith et al., 2001).
4.2 Have the 3Rs been applied fully?
Widespread support for the 3Rs principle does not always
translate into action on the ground, for a variety of rea-
sons (e.g. Coulter et al., 2009; Lloyd et al., 2008; Prescott
and Buchanan-Smith, 2007). Eﬀective implementation of all
three “R”s requires researchers, regulators and members of
scientiﬁc and ethical review committees to be aware of ex-
isting 3Rs approaches and methods, to put the knowledge
base into practice (not just around individual experiments,
but also whole research programmes and strategies), and to
keep abreast of developments in science and technology that
can impact on the 3Rs.
4.2.1 Replacement
Opportunities for replacing the use of NHPs in research and
testing are currently limited, although in vitro methods, hu-
man volunteers, and genetically-altered rodents all have po-
tential (Scientiﬁc Committee on Health and Environmental
Risks, 2009). A more concerted and collaborative eﬀort is
needed to accelerate the development of replacement alter-
natives to NHP use, since this is the only way that the asso-
ciated ethical issues can be addressed wholesale; this often
gets overlooked in the rhetoric surrounding NHP use.
The use of rodents or other vertebrates in place of NHPs is
not replacement as deﬁned by Russell and Burch (1959) but
may be ethically desirable if an assessment of the available
evidence suggests that the non-primate species is likely to
suﬀer less harm. The judgements in such cases can be com-
plex: for example, the transgenic mouse model for neurovir-
luence and potency testing of poliomyelitis vaccines avoids
NHPs but involves greater numbers of animals and more se-
vere endpoints (Dragunsky et al., 2003).
4.2.2 Reduction
There is considerable scope for reduction where NHP use
is currently unavoidable. Appropriate design of experi-
ments is critical and greater consideration should be given to
this during peer review of research proposals and scientiﬁc
manuscripts (Kilkenny et al., 2009). The number of animals
used in each experiment should be the minimum suﬃcient to
answer the question posed, and researchers should justify the
number of animals required, including sample size calcula-
tions where appropriate. Estimates of the number of animals
neededshould, wherepossible, takeintoaccounttherequired
statistical signiﬁcance and power level, the likely magnitude
of the treatment eﬀect (or other outcomes), the population
variance and the factors that might aﬀect this. Opportunities
to further reduce the number of animals used, for example
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by careful planning and scheduling of breeding and experi-
ments, should be exploited.
Sharing of study designs, data and experience, particularly
in industry, can lead to signiﬁcant reductions in NHP use
(even without the need for regulatory change). For example,
a data-sharing collaboration between the NC3Rs and phar-
maceutical and biotechnology companies world-wide has
identiﬁed opportunities to up to halve the number of NHPs
used in the development of mAbs by decreasing the number
of dose groups, recovery animals and chronic studies per-
formed (Chapman et al., 2009). Hence, it is important to
adopt a ﬂexible, case-by-case approach to study design and
drug development, based on strong scientiﬁc rationales.
Exploitation of modern technologies (e.g. in vivo imaging,
telemetry systems, multi-unit electrophysiological recording
techniques) can lead to reduction, for example, through in-
creased data yield per animal and/or experiment (Baker et al.,
1999; Kinter and Johnsen, 1999; t’Hart et al., 2006). Bank-
ing and sharing of tissues within and between establishments
is another means of optimising and reducing NHP use.
The re-use of NHPs can decrease the number of animals
used overall and may be driven by ethical, practical and eco-
nomic considerations. However, there are ethical consider-
ations against as well as in favour of re-use (van Vlissin-
gen, 1999). The actual or potential harms to the animals
concerned (e.g. from long-term housing and the cumulative
eﬀects of previous procedures) must be weighed against the
welfare cost of obtaining and housing (and in some cases
surgically-preparing)na¨ ıveanimals. IntheUK,re-useissub-
ject to legal constraints (Home Oﬃce, 2000) and a reduction
in the overall number of NHPs used is not considered to jus-
tify causing a signiﬁcant increase in harms for individual an-
imals. Similarly, the European Commission (2008) proposes
to restrict the circumstances in which animals can be re-used
in order to limit the harm caused to individual animals.
4.2.3 Reﬁnement
Reﬁnement is misunderstood by many researchers (National
Centre for the Replacement, Reﬁnement and Reduction of
Animals in Research, 2008); it refers to any approach which
avoids or minimises the actual or potential pain, distress and
other adverse eﬀects experienced at any time during the life
of the animals involved, and which enhances their wellbe-
ing (Buchanan-Smith et al., 2005). Reﬁnement is important
not just for ethical reasons, but also for scientiﬁc reasons be-
cause an animal’s welfare state can aﬀect its suitability as a
research model. Developments in animal welfare science are
providing increasingly more sophisticated and reliable mea-
sures of animal suﬀering and well-being (e.g. Mendl et al.,
2009).
Many opportunities exist to reﬁne the use and care of
NHPs and much guidance is available in the scientiﬁc lit-
erature (see Rennie and Buchanan-Smith, 2006a, b, c and
Joint Working Group on Reﬁnement, 2009 for recent re-
views). Researchers should ensure that every aspect of the
lifetime experience of the animals is reﬁned, including sourc-
ing and transport; housing and husbandry; experimental de-
sign and techniques; handling; care of the animals before,
during and after each procedure; end-points of the proce-
dures; and method of killing (or other fate at the end of
the experiments). The possibilities for further reﬁnements
should be continually reviewed throughout the research pro-
gramme.
The high intelligence of NHPs permits behavioural man-
agement techniques to be used to reduce the amount of
stress experienced during capture, transport, maintenance
and research use; such techniques should be integrated into
human-NHP interactions (Prescott and Buchanan-Smith,
2003; Prescott et al., 2005; Schapiro et al., 2005). Estab-
lishing appropriate relationships with NHPs is important for
animal welfare generally and is of special relevance to many
types of NHP research where the researchers depend on the
co-operation of the animal to perform behavioural and cog-
nitive tasks (Prescott et al., 2010)
4.3 Is the NHP use morally justiﬁed?
Even where it is necessary to use NHPs to achieve a particu-
lar scientiﬁc objective, and the 3Rs have been full applied, it
does not mean that it is right to do so. What one person may
consider a morally justiﬁed use of NHPs another may not
(e.g. see the exchange of views on stroke research: Degeling
and Johnson, 2009; Fox, 2009; Gerrek, 2009; Nobis, 2009;
Sughrue et al., 2009a, b; and endotoxic shock: James, 2006;
Wolfensohn et al., 2006; Yin et al., 2005, 2006). In prac-
tice, the test of the moral justiﬁability of NHP use in scien-
tiﬁc procedures is whether or not the likely harms caused to
the NHPs involved are outweighed by the anticipated beneﬁt
for humans (or other animals or the environment) A critical
question is: what counts as a signiﬁcantly important beneﬁt?
A focus of the animal protection community has been the
use of NHPs in fundamental research. Such research pro-
duces information that may come to be useful in understand-
ing and treatment of disease, but is mainly pursued with
the aim of advancing general knowledge in the biological
sciences. For example, much neuroscience research using
NHPs is conducted to understand how the structure and func-
tion of the brain contributes to perception, thinking, emotion
and motor control (e.g. how brain circuits enable us to see,
remember what we have seen, or to reach out and grasp an
object). Some people deny that such experimentation plays a
vitalroleinthedeliveryofsubstantialnewhumanhealthben-
eﬁts, or consider it to have less value than applied research
(German, 2008; Martin, 2009; Sauer, 2004; Schiermeier,
2008). After lobbying on this issue by animal protection
groups, the European Commission (2008) proposed to limit
NHP use under the revised Directive 86/609/EEC to pro-
cedures “undertaken with a view to the avoidance, preven-
tion, diagnosis ortreatmentof life-threatening ordebilitating
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clinical conditions in human beings”, but faced counter-
lobbying by the bioscience community (Olsson and Vitale,
2010). Whilst there have been serendipitous medical ad-
vances stemming from the unexpected outcomes of funda-
mental research, there has never been a robust and systematic
retrospective review of the value and impact of such research
and whether the scientiﬁc advances in the ﬁeld have been
solely dependent on the use of NHPs. This makes generic
statements about NHP use being essential for improving hu-
man health diﬃcult to substantiate.
In order for a robust harm-beneﬁt assessment to be under-
taken, the researcher should set out the anticipated beneﬁts
in precise and realistic terms, the likelihood of success, all
of the harms caused to the animals (with an indication of
the nature, frequency, duration and overall severity of ani-
mal suﬀering), any ethical issues arising from the proposed
work, and why he/she personally considers that the potential
beneﬁts outweigh the harms. Members of the ethics commit-
tee must then make their own judgements about whether the
likely human dividends are substantial enough to outweigh
the animal suﬀering (for practical guidance on making such
judgements, see Animal Procedures Committee, 2003; Smith
and Boyd, 1991). Discussion and debate between committee
members will help to clarify the issues and decide opinions.
There may be disagreement about what is morally accept-
able, in which case the consensus view is usually adopted.
Whatever the ultimate decision, it should be defensible in
the public arena.
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